Effects of local low-dose rocuronium on the quality of peribulbar anesthesia for cataract surgery

Efficacy of adjuvants in ophthalmic regional anesthesia: A systematic review and network meta-analysis

PURPOSE

This network meta-analysis aims to determine the differences between adjuvants that are used in combination with local anesthetics for ophthalmic regional anesthesia.

DESIGN

Systematic review and network meta-analysis METHODS: A systematic literature search for randomized controlled trials, comparing the impact of adjuvants in ophthalmic regional anesthesia, in Embase, CENTRAL, MEDLINE and Web of Science was performed. Risk of bias was evaluated using the Cochrane risk of bias tool. Frequentist network meta-analysis was performed using a random effects model with saline as the comparator. Primary endpoints were the onset and the duration of sensory block and globe akinesia, as well as the duration of analgesia. Summary measure was the ratio of means (ROM). Secondary endpoints were the rates of side effects and adverse events.

RESULTS

39 trials were identified as eligible for network meta-analysis, including 3046 patients. 17 adjuvants were compared in the most extensive network (onset of globe akinesia). The addition of fentanyl (F), clonidine (C) or dexmedetomidine (D) showed the best overall results. Onset of sensory block: F 0.58 [CI 0.47-0.72], C 0.75 [0.63-0.88], D 0.71 [0.61-0.84], onset of globe akinesia: F 0.71 [0.61-0.82], C 0.70 [0.61-0.82], D 0.81 [0.71-0.92], duration of sensory block: F 1.20 [1.14-1.26], C 1.22 [1.18-1.27], D 1.44 [1.34-1.55], duration of globe akinesia: F 1.38 [1.22-1.57], C 1.45 [1.26-1.67], D 1.41 [1.24-1.59], duration analgesia: F 1.46 [1.33-1.60], C 1.78 [1.63-1.96], D 1.41 [1.28-1.56].

CONCLUSION

The addition of fentanyl, clonidine or dexmedetomidine showed beneficial effects regarding onset and duration of sensory block and globe akinesia.

Levobupivacaine Combined with Cisatracurium in Peribulbar Anaesthesia in Cats Undergoing Corneal and Lens Surgery

The aims of the study included evaluating the effects of levobupivacaine combined with cisatracurium on akinesia and mydriasis when administered by peribulbar injection, and evaluating if the chosen dose of cisatracurium is enough to avoid the use of systemic neuromuscular blockade in cats. The animals were divided into four groups as follows: group L received 1.25 mg kg^-1 levobupivacaine administered by peribulbar injection; group LC received the same dose of levobupivacaine combined with 0.01 mg kg^-1 of cisatracurium administered by peribulbar injection; group C received 0.01 mg kg^-1 of cisatracurium administered by peribulbar injection; group GC received 0.01 mg kg^-1 of cisatracurium intravenously. Physiological variables, intraocular pressure, akinesia, and mydriasis were measured before and up to 30 min after peribulbar injection. The onset of akinesia, duration of akinesia, and train of four (TOF) were evaluated. Physiological variables remained in the physiological range in all groups. Effective akinesia and mydriasis were observed in all groups. The (TOF) was 0.9 in all groups. Throughout the study was observed in group LC a shortened onset of akinesia and a prolonging its duration. The peribulbar injection of cisatracurium and levobupivacaine provided effective akinesia and mydriasis, and shortened the onset of akinesia while prolonging its duration.

Dexmedetomidine as an additive to local anesthetics compared with intravenous dexmedetomidine in peribulbar block for cataract surgery

Background:

No studies compared parenteral dexmedetomidine with its use as an adjuvant to ophthalmic block. We compared between adding dexmedetomidine to bupivacaine in peribulbar block and intravenous (IV) dexmedetomidine during peribulbar block for cataract surgery.

Materials and Methods:

A prospective, randomized, double-blind study on 90 patients for cataract surgery under peribulbar anesthesia. Study included three groups; all patients received 10 ml of peribulbar anesthesia and IV infusion of drugs as follows: Group I: Received a mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + normal saline (1 ml) + 150 IU hyaluronidase + IV infusion of normal saline, Group II: Received mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + dexmedetomidine 50 μg (1 ml) +150 IU hyaluronidase + IV infusion of normal saline and Group III: Received mixture of bupivacaine 0.5% (4.5 ml) + lidocaine 2% (4.5 ml) + normal saline (1 ml) +150 IU hyaluronidase + IV dexmedetomidine 1 μg/kg over 10 min; followed by 0.4 μg/kg/h IV infusion. We recorded onset, duration of block, Ramsay Sedation Score, intra-ocular pressure (IOP), hemodynamics, and adverse effects.

Results:

There was a significant decrease in the onset of action and increase in the duration of block in Group II as compared with the Group I and Group III. Mean Ramsay Sedation Score was higher in Group III. The IOP showed a significant decrease in Group II and Group III 10 min after injection (P < 0.01). Heart rate showed a significant decrease in Group III in comparison with the two other groups (P < 0.05). Only two patients in Group III developed bradycardia.

Conclusion:

Dexmedetomidine as an additive shortens onset time, prolong block durations and significantly decreases the IOP with minimal side effects. IV dexmedetomidine, in addition, produces intra-operative sedation with hemodynamic stability.

Efficacy and safety of dexmedetomidine as an additive to local anesthetics in peribulbar block for cataract surgery

Background and Objectives:

We evaluated the effect of adding dexmedetomidine to lidocaine and bupivacaine for peribulbar block in two different doses. The primary endpoints were the onset and duration of corneal anesthesia, globe akinesia, and duration of analgesia.

Materials and Methods:

A randomized controlled clinical trial was conducted on 90 ASA I-II patients scheduled for elective cataract surgery under peribulbar anesthesia. Patients were randomly allocated to one of three groups of 30 each; group C (control) received 3 ml of 2% lidocaine with 3 ml of 0.5% bupivacaine; group D₅₀ received 3 ml of 2% lidocaine with 3 ml of 0.5% bupivacaine and 50 ug of dexmedetomidine; and group D₂₅ received 3 ml of 2% lidocaine with 3 ml of 0.5% bupivacaine and 25 μg of dexmedetomidine.

Results:

The onset of corneal anesthesia and globe akinesia was significantly shorter in group D₅₀ (P < 0.001) as compared to group C; however, in Group D₂₅ onset of corneal anesthesia was significantly faster, but not onset of globe akinesia (P = 0.45). The duration of corneal anesthesia and globe akinesia was significantly longer (P < 0.001) in both Group D₅₀ and Group D₂₅ in comparison to Group C. Decrease in IOP was observed in both group D₅₀ and group D₂₅ at 5 minutes and 10 minutes following peribulbar block which was significant (P < 0.05) compared to group C.

Conclusion:

Addition of dexmedetomidine to lidocaine and bupivacaine in peribulbar block shortens the onset time and prolongs the duration of the block and postoperative analgesia. It also provides sedation which enables full cooperation and potentially better operating conditions.

Pharmacological interventions for acceleration of the onset time of rocuronium: a meta-analysis

BACKGROUND

Rocuronium is an acceptable alternative when succinylcholine is contraindicated for facilitating the endotracheal intubation. However, the onset time of rocuronium for good intubation condition is still slower than that condition of succinylcholine. This study systematically investigated the most efficacious pharmacological interventions for accelerating the onset time of rocuronium.

METHODS

Medline, Embase, Cochrane Library databases, www.clinicaltrials.gov, and hand searching from the reference lists of identified papers were searched for randomized controlled trials comparing drug interventions with placebo or another drug to shorten the onset time of rocuronium. Statistical analyses were performed using RevMan5.2 and ADDIS 1.16.5 softwares. Mean differences (MDs) with their 95% confidence intervals (95% CIs) were used to analyze the effects of drug interventions on the onset time of rocuronium.

RESULTS

43 randomized controlled trials with 2,465 patients were analyzed. The average onset time of rocuronium was 102.4±24.9 s. Priming with rocuronium [Mean difference (MD) -21.0 s, 95% confidence interval (95% CI) (-27.6 to -14.3 s)], pretreatment with ephedrine [-22.3 s (-29.1 to -15.5 s)], pretreatment with magnesium sulphate [-28.2 s (-50.9 to -5.6 s)] were all effective in reducing the onset time of rocuronium. Statistical testing of indirect comparisons showed that rocuronium priming, pretreatment with ephedrine, and pretreatment with magnesium sulphate had the similar efficacy.

CONCLUSION

Rocuronium priming, pretreatment with ephedrine, and pretreatment with magnesium sulphate were all effective in accelerating the onset time of rocuronium, and furthermore their efficacies were similar. Considering the convenience and efficacy, priming with rocuronium is recommended for accelerating the onset time of rocuronium. However, more strict clinical trials are still needed to reach a more solid conclusion due to the large heterogeneities exist among different studies.